LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ: LIMN · HEALTHCARE · BIOTECHNOLOGY
$0.20
-0.15% today
Updated 2026-04-30
Market cap
$9.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$0 – $34
Volume
5.0M
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $-1.22M | $-869000.00 | $-3.35M | $-3.11M | $-9.96M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $13108.00 |
| Depreciation | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — |
| Free cash flow | $-1.22M | $-869000.00 | $-3.35M | $-3.11M | $-9.98M |
| Investing cash flow | $-276.00M | $263.96M | $-819000.00 | $1.97M | — |
| Financing cash flow | $277.55M | $5.92M | $-450000.00 | $1.05M | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt repayment | — | — | — | — | — |
| Net change in cash | — | — | — | — | — |